Jessica Schiffbauer, OD
Optometrist · Kenosha, WINPI 1659723328
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.2%), education and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AbbVie at 27.3% of the total. Reporting peaked in 2022 at $12,389 and has fallen 98.1% since, to $232 in 2025. Among optometrist clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $125.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Sun Pharmaceutical Industries Inc.$7K
- Bausch & Lomb Americas Inc.$2K
- Eyevance Pharmaceuticals LLC$2K
- Tarsus Pharmaceuticals, Inc.$1K
- Carl Zeiss Meditec USA, Inc.$1K
- plus $7K from 27 others
What the payments were for
- Consulting fees$3,65014%
- Speaking & faculty fees$5,02619%
- Travel & lodging$2,66810%
- Food & beverage$8,82533%
- Education$6,42024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $7,254 |
| Sun Pharmaceutical Industries Inc. | 10 | $6,644 |
| Bausch & Lomb Americas Inc. | 24 | $1,687 |
| Eyevance Pharmaceuticals LLC | 3 | $1,596 |
| Tarsus Pharmaceuticals, Inc. | 9 | $1,307 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,178 |
| Alcon Research LLC | 3 | $1,000 |
| Biotissue Holdings Inc. | 12 | $779 |
| Alcon | 5 | $755 |
| Rxsight Inc | 8 | $495 |
| Dompe US, Inc. | 9 | $432 |
| Amgen(2 entities) | 8 | $322 |
| Harrow Eye, LLC | 10 | $302 |
| Aerie Pharmaceuticals, Inc. | 7 | $289 |
| NEW World Medical,inc. | 4 | $256 |
| Novartis | 8 | $246 |
| Mallinckrodt Hospital Products Inc. | 4 | $225 |
| Astellas Pharma US Inc | 4 | $224 |
| Sight Sciences, Inc. | 3 | $218 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $216 |
| Kala Pharmaceuticals, Inc. | 6 | $215 |
| Alimera Sciences, Inc. | 1 | $164 |
| Apellis Pharmaceuticals, Inc. | 3 | $158 |
| Glaukos Corporation | 1 | $115 |
| Sanofi | 1 | $104 |
| Shire North American Group Inc | 2 | $87 |
| Quidel Corporation | 1 | $78 |
| Oyster Point Pharma, Inc. | 3 | $77 |
| Thea Pharma Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Lensar, Inc. | 1 | $22 |
| Omeros Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$6,327
- VUITY$5,755
- VisuMax$1,178
- XDEMVY$1,132
- Tobradex ST$1,000
- enVista Aspire IOL$984
- TENEO$984
- STELLARIS ELITE$984
- Rhopressa$614
- Flarex$500
- RXSIGHT INJECTOR HANDPIECE$368
- RXSIGHT CONTACT LENS$368
- RXSIGHT INJECTOR CARTRIDGE$368
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$368
- LUMIGAN$338
- RESTASIS$262
- LIGHT ADJUSTABLE LENS (LAL)$250
- Kahook Dual Blade$240
- Clearpath$240
- Ahmed Glaucoma Valve$240
How this compares
$26,589 in reported general payments places this provider in the 95th percentile of 867 optometrist providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 127 | $135,300 |
| XiidraLifitegrast | 59 | $73,445 |
| XdemvyLotilaner | 36 | $71,596 |
| VyzultaLatanoprostene Bunod | 81 | $36,562 |
| Cyclosporine | 43 | $24,634 |
| LumiganBimatoprost | 57 | $22,330 |
| MieboPerfluorohexyloctane/Pf | 19 | $14,329 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 69 | $14,277 |
| TyrvayaVarenicline Tartrate | 18 | $11,630 |
| IlevroNepafenac | 29 | $10,826 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $9,653 |
| Bromfenac Sodium | 30 | $7,828 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $7,476 |
| Lotemax SmLoteprednol Etabonate | 27 | $6,911 |
| ProlensaBromfenac Sodium | 19 | $6,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $7,254 | $165,106208 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,687 | $124,336159 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,307 | $71,59636 claims |
| AlconSimbrinza | $755 | $14,27769 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $216 | $13,55646 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $77 | $11,63018 claims |
| NovartisIlevro | $246 | $10,82629 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $289 | $9,65327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 867 optometrist providers in Wisconsin.
Other optometrist in Kenosha
- David NelsonMadison$256K
- Jennifer FrieheMukwonago$234K
- Tessa SokolMadison$105K
- Christopher LopezClintonville$48K
- Jeff BanasMount Pleasant$46K
- Jeffrey ClementsSun Prairie$16K
- Douglas HinsonSturtevant$15K
- Marcus NeitzkeWaukesha$14K
- Michelle KwonHartford$12K
- Amber DentzHartland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.